Oculis Holding Surges 6.2% as Privosegtor & OCS‑01 Advance, Yet Negative P/E Sparks Investor Caution
Oculis Holding AG’s clinical wins—Privosegtor FDA nod and OCS‑01 Phase 3 readouts—boost its shares 6.2 %, but a negative P/E warns investors to watch financial sustainability while the biotech targets high‑impact retinal therapies.
3 minutes to read

